Skip to main content

Healon Side Effects

Generic name: sodium hyaluronate ophthalmic

Medically reviewed by Drugs.com. Last updated on Aug 4, 2023.

Note: This document contains side effect information about sodium hyaluronate ophthalmic. Some dosage forms listed on this page may not apply to the brand name Healon.

Applies to sodium hyaluronate ophthalmic: intraocular solution.

Serious side effects of Healon

WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:

Other side effects of Healon

All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:

These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.

You may report side effects to the FDA at 1-800-332-1088. You may also report side effects at https://www.fda.gov/medwatch.

For Healthcare Professionals

Applies to sodium hyaluronate ophthalmic: intraocular kit, intraocular liquid.

Ocular

Ocular side effects have included isolated reports of diffuse particulates or haziness appearing after injection of sodium hyaluronate ophthalmic (the active ingredient contained in Healon) into the eye. Transient postoperative increases in intraocular pressure have been observed following the use of sodium hyaluronate in anterior segment surgery. On rare occasions, postoperative reactions including inflammation, corneal edema, and corneal decompensation have been reported.[Ref]

More about Healon (sodium hyaluronate ophthalmic)

Patient resources

Other brands

Provisc, Amvisc, Amvisc Plus

Related treatment guides

References

1. Schrader J, Luders S, Kulschewski A, et al. Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity and mortality in essential hypertension: final results of a prospective long-term study (MARPLE Study)* J Hypertens. 2006;24:541-548.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.